KCAS Bioanalytical and Biomarker Services Welcomes Executive Director of Bioanalytical R&D and LC-MS/MS Services

Share Article

Lawrence Goodwin has significant drug development aptitude in both the pharmaceutical and CRO industries where he has led teams responsible for bioanalytical programs from Discovery through New Drug Application filings.

His leadership is a critical component of KCAS' development strategy to become a leader in stand-alone bioanalytical service providers who have the speed, expertise and superior service to be competitive in the biotech and pharmaceutical industry.

KCAS Bioanalytical and Biomarker Services, a leading service contract research organization (CRO) is pleased to announce the expansion of their Bioanalytical Services technical team. Mr. Lawrence Goodwin joins KCAS as Executive Director of Bioanalytical R&D and LC-MS/MS Services.

Mr. Goodwin's reputation is that of providing business growth strategies and client-based solutions within the CRO industry by evaluating and implementing new instrumentation and technologies to increase analytical sensitivity, productivity and capabilities. Mr. Goodwin brings with him the breadth of knowledge to provide scientific and technical leadership across the drug development spectrum including Discovery, Safety Assessment and Biologics Testing Solutions areas.

"Lawrence Goodwin has significant drug development aptitude in both the pharmaceutical and CRO industries where he has led teams responsible for bioanalytical programs from Discovery through New Drug Application filings. His experience leading labs at the global level will undoubtedly raise the bar in KCAS' ability to serve our clients. His leadership is a critical component of KCAS' development strategy to become a leader in stand-alone bioanalytical service providers who have the speed, expertise and superior service to be competitive in the biotech and pharmaceutical industry." stated John Bucksath, CEO.

Mr. Goodwin joins KCAS from Charles River Laboratories where he oversaw bioanalytical, analytical, biotherapeutic characterization and formulation development services. Previously he worked for Eli Lilly and Company and Quintiles in technical and management roles within discovery chemistry and analytical technologies. He currently is a member of the Greater Boston Mass Spectrometry Society and the American Society for Mass Spectrometry. Mr. Goodwin earned his Bachelor of Science in Biological Chemistry with Honors from Fontbonne University in St Louis, MO.

"It is refreshing to be a part of a growing organization committed to delivering quality scientific solutions to our existing and future clients. One of the most exciting opportunities at KCAS is to work with our high level scientific staff and leveraging our LC-MS/MS platforms to bring on-board an integrated drug discovery program, to move clients' compounds through the drug discovery pipeline." stated Lawrence Goodwin.

About KCAS
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS' team leverages a highly scientific staff with an average tenure of 10 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com

Share article on social media or email:

View article via:

Pdf Print